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Homeostasis of the blood vasculature relies on a single layer of endothelial cells (ECs) forming the inner surface of all vessels. In most adult tissues, ECs reside in a non-cycling, 
quiescent state, which is critical for their function as a barrier and 
signalling interface1,2. This resting state is reversible, and ECs can 
(re-)activate, enter the cell cycle and expand to meet physiologi-
cal or stress-induced demands. While the processes of endothe-
lial activation and proliferation are being defined with increasing 
molecular resolution, the mechanisms leading to the acquisition of 
a quiescent phenotype remain poorly understood.
Previous studies have demonstrated that the forkhead box 
O (FOXO) transcription factor FOXO1 is a critical driver of 
endothelial quiescence3,4. FOXO1 activity is controlled by the 
phosphatidylinositol-3-OH kinase–AKT pathway that inhibits 
FOXO1 transcriptional responses through AKT-mediated phos-
phorylation5,6. ECs are highly sensitive to changes in FOXO1 activ-
ity, as both EC-specific deletion and forced activation are early 
embryonic lethal in mice3,4,7,8. Loss of FOXO1 leads to unregulated 
endothelial proliferation and vascular overgrowth, whereas forced 
activation causes premature quiescence and vascular rarefaction. 
FOXO1 promotes quiescence, in part, by suppressing MYC signal-
ling, which leads to a reduction in endothelial metabolic activity4. 
Yet, the FOXO1-regulated metabolic programmes in ECs are largely 
unknown. Given the importance of endothelial metabolic regula-
tion for vascular growth and function9–19 and the sensitivity of ECs 
towards changes in FOXO1 activity, we sought to investigate the 
global metabolic profile of FOXO1-induced ECs.
Results
FOXO1 activation induces 2-hydroxyglutarate generation in ECs. 
We performed untargeted metabolomics of human umbilical vein 
endothelial cells (HUVECs) that were transduced with adenovi-
ruses encoding a constitutively active FOXO1 mutant (AdFOXO1A3) 
or green fluorescent protein (GFP) as a control (AdCtrl). This 
mutant has the three AKT phosphorylation sites replaced by ala-
nine (→FOXO1A3), which renders FOXO1 in the nucleus5,6. ECs 
expressing FOXO1A3 were in a reversible proliferation arrest and 
exhibited a molecular signature characteristic of cellular quiescence, 
including suppression of the proliferation markers MYC and prolif-
erating cell nuclear antigen (PCNA), as well as induction of the cell 
cycle inhibitor p27 (CDKN1B) and the repressive histone mark his-
tone H3 lysine 27 trimethylation (H3K27me3)20–23 (Extended Data 
Fig. 1a–c,f).
Principal component analysis (PCA) of the intracellular metabo-
lites collected 24 h post-transduction revealed a separate clustering 
of control and FOXO1A3-transduced ECs (Fig. 1a). ECs with nuclear 
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Endothelial cells (ECs) adapt their metabolism to enable the growth of new blood vessels, but little is known how ECs regulate 
metabolism to adopt a quiescent state. Here, we show that the metabolite S-2-hydroxyglutarate (S-2HG) plays a crucial role 
in the regulation of endothelial quiescence. We find that S-2HG is produced in ECs after activation of the transcription factor 
forkhead box O1 (FOXO1), where it limits cell cycle progression, metabolic activity and vascular expansion. FOXO1 stimulates S-
2HG production by inhibiting the mitochondrial enzyme 2-oxoglutarate dehydrogenase. This inhibition relies on branched-chain 
amino acid catabolites such as 3-methyl-2-oxovalerate, which increase in ECs with activated FOXO1. Treatment of ECs with 
3-methyl-2-oxovalerate elicits S-2HG production and suppresses proliferation, causing vascular rarefaction in mice. Our find-
ings identify a metabolic programme that promotes the acquisition of a quiescent endothelial state and highlight the role of 
metabolites as signalling molecules in the endothelium.
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FOXO1 exhibited increased levels of several branched-chain amino 
acid (BCAA) metabolites and of early tricarboxylic acid (TCA) 
cycle intermediates (Supplementary Table 1). Notably, the most 
increased metabolite (7.6-fold) was 2-hydroxyglutarate (2HG) 
(Fig. 1b and Extended Data Fig. 1d), which is a chiral molecule 
derived from 2-oxoglutarate (2OG) that functions as a competi-
tive inhibitor of many 2OG-dependent dioxygenases. Among these 
are Jumonji C (JmjC) domain-containing lysine demethylases and 
hypoxia-inducible factor (HIF)-regulating prolyl hydroxylases 
(PHDs)24–29, which suggests that FOXO1 may exert profound effects 
on gene expression via regulation of this metabolite.
We therefore confirmed the regulation of 2HG using a lentivi-
ral system for doxycycline-inducible expression of FOXO1A3 (Fig. 
1c and Extended Data Fig. 1e) and contact inhibition of endothe-
lial proliferation—a stimulus for nuclear translocation and activa-
tion of endogenous FOXO1 (Fig. 1e–i and Extended Data Fig. 1g). 
Indeed, we observed an 8.4-fold increase in 2HG abundance in 
dense (contact-inhibited) culture conditions, whereby FOXO1 is an 
induced and predominantly nuclear protein and in which canoni-
cal FOXO1 target genes are highly transcribed (for example, MAX 
interactor 1 (MXI1), pyruvate dehydrogenase kinase 1 (PDK1), 
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Fig. 1 | Activation of FOXO1 signalling induces the generation of S-2HG in eCs. a, PCA score plot showing distinct metabolic signatures in control (AdCtrl) 
and FOXO1A3-expressing (AdFOXO1A3) HUVECs (n = 4 independent samples). The percentage variance explained by each principal component (PC) is 
shown in parentheses. b, Volcano plot of metabolites showing 2HG as the most increased metabolite in FOXO1A3-expressing HUVECs. c, 2HG metabolite 
levels measured by LC–MS in HUVECs transduced with a doxycycline-inducible control-encoding (iLentiCtrl) or FOXO1A3-encoding (iLentiFOXO1A3) 
lentivirus (n = 8 independent samples). AU, arbitrary units. d, Chiral derivatization and enantioselective LC–MS measurement of R- and S-2HG levels 
in HUVECs transduced with iLentiCtrl or iLentiFOXO1A3 (n = 8 independent samples). e, Immunoblot analysis of HUVECs cultured in sparse and dense 
conditions. HUVECs in dense (contact-inhibited) conditions express markers linked to cellular quiescence. K, 1,000. f,g, Immunofluorescence analysis 
(f) and quantification (g) of the subcellular localization of FOXO1 (red) in HUVECs cultured in sparse and dense conditions. The isolated FOXO1 signal is 
shown on the right side of each image in grey (n = 14 (sparse condition) or 8 (dense condition) independent samples). DAPI (grey), nuclei; PECAM (cyan), 
intercellular endothelial junctions. Cyto, cytoplasmic; Nuc, nuclear; Nuc–cyto, nuclear–cytoplasmic. h, FOXO1 protein levels in cytoplasmic and nuclear 
fractions isolated from HUVECs cultured under sparse and dense conditions. Lamin A/C and tubulin were used as nuclear and cytoplasmic markers, 
respectively. i, 2HG metabolite levels in HUVECs cultured in sparse (FOXO1 inactive) and dense (FOXO1 active) culture conditions (n = 7 independent 
samples). j, Enantioselective LC–MS measurement of R- and S-2HG in sparse and dense HUVEC cultures (n = 7 independent samples). Western blot data 
in e and h are from the respective experiment, processed in parallel, and are representative of at least three independent experiments. For c, d, g, i and 
j, data represent the mean ± s.e.m.; two-tailed unpaired t-test, ****P < 0.0001, NS, not significant. The numerical data, unprocessed western blots and P 
values are provided as source data.
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(CD36)) (Fig. 1f–i and Extended Data Fig. 1g). Thus, ECs generate 
2HG when FOXO1 signalling is activated.
FOXO1-activated ECs produce S-2HG, which inhibits 
2OG-dependent dioxygenases. Two conformations of 2HG exist, 
the R-2HG and S-2HG enantiomers, which have similar but not 
identical functions30–32. Chiral derivatization followed by liquid chro-
matography–mass spectrometry (LC–MS) revealed that FOXO1 
induces the preferential generation of S-2HG, which is also the more 
abundant enantiomer in ECs (Fig. 1d,j). To explore whether 2HG 
regulates the activity of endothelial 2OG-dependent dioxygenases, 
we first analysed HIFs, which are marked by PHDs for proteasomal 
degradation under normoxic conditions. In line with an inhibi-
tory effect of 2HG on PHDs30,31,33–35, incubation of HUVECs with 
cell-permeable forms of R-2HG or S-2HG increased HIF1α and 
HIF2α protein abundance and enhanced HIF target gene expression 
(Extended Data Fig. 2a–c). Interestingly, S-2HG had more profound 
effects on HIF responses than R-2HG (Extended Data Fig. 2a–c). 
Similar results were obtained for H3K27me3, which is targeted by 
the 2OG-dependent JmjC histone demethylases (Extended Data 
Fig. 2d), which suggests that S-2HG is the more potent inhibitor 
of 2OG-dependent dioxygenases in ECs. Therefore, we focused our 
further analysis on this enantiomer.
S-2HG promotes a quiescent endothelial state. To characterize the 
role of S-2HG in ECs, we incubated HUVECs with different S-2HG 
concentrations and noted a time- and dose-dependent suppression 
of endothelial proliferation (Fig. 2a–c and Extended Data Fig. 3a). 
S-2HG-treated ECs were arrested in the G0/G1 phase of the cell 
cycle, and markers of cell growth and proliferation, including MYC, 
PCNA and phosphorylated ribosomal protein S6, were diminished 
(Fig. 2d,e and Extended Data Fig. 3b). S-2HG did not cause meta-
bolic distress (depletion of a particular metabolite), senescence or 
apoptotic cell death, as reporters of these processes were unaltered or 
not detectable (Fig. 2f and Extended Data Fig. 3c–f). To further char-
acterize this antiproliferative effect, we transduced HUVECs with a 
lentiviral vector encoding the fluorescent ubiquitination-based cell 
cycle indicator (FUCCI). This dual-colour reporter labels nuclei 
of cells in the G0/G1 phase in red and those in the S/G2/M phases 
in green (Extended Data Fig. 3g,h). S-2HG caused a progressive 
increase in ECs with red fluorescence, thereby confirming the G0/
G1 arrest (Fig. 2g and Supplementary Videos 1 and 2). However, 
S-2HG withdrawal led to the reappearance of ECs with green fluo-
rescent nuclei (Fig. 2g and Supplementary Videos 1 and 2), which 
indicates that the S-2HG-induced proliferation arrest is reversible.
RNA sequencing (RNA-seq) of HUVECs treated with vehicle 
or S-2HG for 24 h revealed that S-2HG regulates genes strongly 
linked to proliferation (Fig. 2h, Extended Data Fig. 4a–c and 
Supplementary Table 2). A total of 43 out of the 50 most downregu-
lated genes are involved in cell cycle progression and cell division, 
including DNA topoisomerase II alpha (TOP2A), anillin (ANLN), 
marker of proliferation Ki-67 (MKI67) and cyclin-dependent kinase 
1 (CDK1) (Extended Data Fig. 4b). Gene set enrichment analysis 
(GSEA) corroborated this notion (Fig. 2i and Extended Data Fig. 
4c). Moreover, numerous quiescence-associated genes36, including 
those that are not directly linked to cell proliferation, were enriched 
in S-2HG-treated ECs (Fig. 2i). These data suggest that S-2HG reg-
ulates not only endothelial proliferation but also, more generally, 
promotes a quiescent endothelial state. Consistent with this idea, 
S-2HG-treated ECs showed a number of cellular phenotypes that 
are characteristic for quiescent cells23, including lower metabolic 
activity and reduced RNA and protein synthesis (Fig. 2j–m and 
Extended Data Fig. 4d).
S-2HG limits the angiogenic behaviour of ECs. To seek further 
evidence of a quiescence-promoting function of S-2HG, we visu-
alized endothelial angiogenic behaviour in an in vitro scratch 
assay and found that S-2HG-treated ECs were less motile (Fig. 
3a,b and Supplementary Videos 3 and 4). Moreover, analysis of 
three-dimensional endothelial spheroid cultures revealed that 
S-2HG-treated spheroids formed fewer and shorter sprouts com-
pared to controls (Fig. 3c and Extended Data Fig. 5a). We validated 
the relevance of these findings by studying blood vessel growth in 
the mouse retina, in which blood vessels develop postnatally in a 
highly stereotypical manner. Postnatal day 5 (P5) pups received 
a single intraocular injection of S-2HG in one eye and vehicle in 
the other (Extended Data Fig. 5b). Analysis of the retinal vascula-
ture 2 days later (at P7) showed a poorly connected and hypocel-
lular endothelial network in S-2HG-treated retinas (Fig. 3d,e,i and 
Extended Data Fig. 5c). This phenotype was particularly evident 
at the angiogenic front, where most of the endothelial growth and 
proliferation occurs, while central parts of the retinal vasculature 
that formed before the injection were less affected (Fig. 3d,e). The 
sparse network was not due to increased vessel pruning or apop-
totic cell death, since analysis of endothelial-less basement mem-
brane sleeves or cleaved caspase-3-positive ECs did not reveal 
significant changes (Fig. 3g–i). Instead, we found a marked sup-
pression of EC proliferation, which was indicated by a reduction in 
5-ethynyl-2′-deoxyuridine (EdU)-positive endothelial nuclei (Fig. 
3f,i and Extended Data Fig. 5c). These data are consistent with an 
Fig. 2 | S-2HG supports a quiescent endothelial phenotype. a, Growth curves of HUVECs stimulated with DMSO (Ctrl) or cell-permeable S-2HG 
(n = 16 independent samples). b, EdU incorporation in control or S-2HG-treated HUVECs at 48 h. The percentage of EdU-positive ECs is shown (n = 14 
independent samples). c, DNA synthesis is reduced in HUVECs treated with S-2HG for 48 h. Values represent the fold-change relative to DMSO-treated 
HUVECs (n = 8 independent samples). d, Cell-cycle analysis of control and S-2HG-stimulated HUVECs 48 h after treatment (n = 4 independent samples). 
e, Immunoblotting of proliferation and growth-associated proteins in HUVECs treated with S-2HG for 24 h. f, Immunoblot analysis of the apoptotic 
markers cleaved (cl.) caspase-3 (CASP3) and cleaved PARP showing that S-2HG does not cause cell death in HUVECs. TNFα (TNF) and cycloheximide 
(CHX) co-stimulation was used as a positive control. g, Time-course analysis of HUVECs transduced with the dual FUCCI reporter. ECs were treated 
with vehicle or S-2HG for 48 h, followed by withdrawal of the treatment and further analysis for 48 h (n = 3 independent samples). h, Volcano plot of 
differentially expressed genes in control or S-2HG-treated HUVECs at 24 h. Genes with a P value cut-off of ≤0.05 and a fold-change ≥ or ≤2 are shown 
(n = 3 independent samples). i, GSEA plots of quiescent versus dividing-down and quiescent versus dividing-up gene sets in the transcriptomes of control 
or S-2HG-treated HUVECs. ES, enrichment score; FDR, false discovery rate; NES, normalized enrichment score. j, OCRs in control or S-2HG-treated 
HUVECs (n = 9 independent samples). AA/R, antimycin A/rotenone; Oligo, oligomycin. k, ATP levels in HUVECs 48 h after treatment with vehicle or 
S-2HG (n = 4 independent samples). l, RNA synthesis is decreased, as measured by 14C-glucose incorporation into RNA, in HUVECs treated with S-2HG 
for 48 h. Values are represented as the fold-change relative to control (n = 8 independent samples). m, Protein synthesis is decreased, as measured 
by 3H-tyrosine incorporation into protein, in HUVECs treated with S-2HG for 48 h. Values are represented as the fold-change relative to control (n = 8 
independent samples). Western blot data in e and f are from the respective experiment, processed in parallel, and are representative of at least three 
independent experiments. For a–d, g and j–m, the data represent the mean ± s.e.m.; two-tailed unpaired t-test, *P < 0.05, **P < 0.01, ****P < 0.0001. The 
numerical data, unprocessed western blots and P values are provided as source data.
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anti-angiogenic activity of S-2HG in ECs and suggest that S-2HG 
enforces the pro-quiescent function of FOXO1.
FOXO1 induces S-2HG generation by inhibiting the OGDH 
enzyme. Previous studies have shown that S-2HG is generated 
in conditions of reduced mitochondrial function in which 2OG 
becomes promiscuously reduced to S-2HG33–35,37–41. To understand 
how ECs generate S-2HG in response to FOXO1 activation, we 
examined mitochondrial metabolism. This analysis revealed altered 
mitochondrial respiration in FOXO1A3-expressing ECs (Extended 
Data Fig. 6a), which suggests that there is diminished activity of the 
2OG dehydrogenase (OGDH) enzyme—a multisubunit complex 
that catalyses the conversion of 2OG to succinyl-CoA (Extended 
Data Fig. 6b). Indeed, we observed that FOXO1A3-expressing ECs 
accumulated the OGDH substrate 2OG, while succinyl-carnitine—
a surrogate metabolite of succinyl-CoA—was depleted (Fig. 4a and 
Supplementary Table 1). Of note, recent genetic studies identified 
OGDH inhibition as a mechanism for S-2HG generation33,42,43. We 
therefore used the clustered regularly interspaced short palindromic 
repeats (CRISPR)–Cas9 method to specifically inactivate OGDH in 
ECs (Fig. 4b). Transduction of HUVECs with lentiviral constructs 
encoding FLAG-tagged Cas9 (Cas9FLAG) and guide RNAs (gRNAs) 
targeting OGDH (gOGDH) led to the expected accumulation of 2OG 
and a decline in the mitochondrial oxygen consumption rate (OCR) 
(Fig. 4c and Extended Data Fig. 6c). Importantly, OGDH deficiency 
increased endothelial S-2HG levels and abrogated the ability of 
ECs to proliferate (Fig. 4d–g). The growth inhibitory effect was not 
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with (cell permeable) 2OG did not influence their capacity to sprout 
or divide (Fig. 4h and Extended Data Fig. 6d,e). Moreover, it was not 
a generic response to TCA cycle perturbation, because inactivation 
of two other TCA cycle enzymes, succinate dehydrogenase (SDH) 
and fumarate hydratase (FH), neither increased S-2HG levels nor 
inhibited endothelial proliferation (Fig. 4i–k and Extended Data 
Fig. 6f–k). These data suggest a crucial role of OGDH in endothelial 
cell-cycle control, which relies on the signalling metabolite S-2HG.
Endothelial OGDH is crucial for angiogenic growth. To deter-
mine the physiological relevance of these findings, we generated 
mice in which exon 3 and 4 of the Ogdh gene are flanked by loxP 
sites (Ogdhfl) (Extended Data Fig. 7a). Deleting these exons in 
ECs (and some haematopoietic cells) using a constitutive Tie2-cre 
transgene (OgdhEC-KO) caused severe defects in the yolk sac vascu-
lature that led to developmental retardation and embryonic death 
(Fig. 5a,b and Extended Data Fig. 7b,c). To further characterize the 
functional consequences of Ogdh deletion, we analysed blood ves-
sel growth in the postnatal retina. To this end, we bred Ogdhfl mice 
with mice expressing the tamoxifen-inducible recombinase cre-
ERT2 from the endothelial-restricted Cdh5 promoter (OgdhiECKO). 
4-Hydroxytamoxifen (4-OHT)-induced depletion of OGDH caused 
a sparse vascular network that mimicked the defective vasculature 


























































































































Fig. 3 | S-2HG restrains the angiogenic activity of eCs. a,b, S-2HG reduces the motile behaviour of cultured HUVECs in a scratch-wound assay. 
Quantification (a) and representative bright-field images (b) from control and S-2HG-treated HUVECs (n = 15 independent samples). c, Confocal 
images of phalloidin-labelled (grey) HUVEC spheroids showing reduced endothelial sprouting in S-2HG treated spheroids. Images were taken 24 h after 
treatment. d, PECAM1 (PECAM) immunofluorescence staining (grey) in P7 mouse retinas showing decreased vascular density after a single intravitreal 
injection of cell-permeable S-2HG at P5. Controls were obtained by injection of DMSO (vehicle, Ctrl) in the contralateral eye. A, artery; AF, angiogenic 
front; CP, capillary plexus; V, vein. e, Confocal images of P7 retinas from control and S-2HG-injected mice stained for ERG (cyan) and PECAM (red). 
f, Immunofluorescence staining for EdU (red), ERG (green) and PECAM (blue) in P7 mouse retinas of control and S-2HG mice. Proliferating (EdU and 
ERG double-positive) ECs are shown in yellow. g, Confocal images of retinas from control and S-2HG-injected mice stained for ICAM2 (ICAM, green), 
PECAM (blue) and collagen IV (COL, red). h, Immunofluorescence images of cleaved caspase-3 (yellow), ICAM (cyan) and PECAM (red) of P7 retinas 
from control and S-2HG-injected mice, excluding excessive apoptotic cell death in S-2HG-treated mice. Note that most of the cleaved caspase-3 signals 
come from nonvascular (ICAM/PECAM-negative) cells. i, Quantification of angiogenic parameters in retinas of control and S-2HG-injected P7 mice, as 
indicated (EC area: n = 21 samples each for control and S-2HG; EC proliferation: n = 24 each samples for control and S-2HG; regression index: n = 18 and  
22 samples for control and S-2HG, respectively). For a and i, the data represent the mean ± s.e.m.; two-tailed unpaired t-test, ****P < 0.0001.  
The numerical data and P values are provided as source data.
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Data Fig. 7d–g). Ogdh mutant ECs had elevated S-2HG levels and 
exhibited diminished proliferation, but lacked signs of increased cell 
death (Fig. 5e–i and Extended Data Fig. 7f,g). This result under-
scores the importance of OGDH function for endothelial prolifera-
tion and vascular growth control.
FOXO1 inhibits OGDH function via the generation of BCAA 
catabolites. We then investigated the mechanisms through which 
FOXO1 regulates OGDH function. First, we examined whether 
FOXO1 regulates the expression of components of the OGDH 
complex. For this purpose, we performed RNA-seq analysis in 
control and FOXO1A3-expressing HUVECs. While FOXO1 gov-
erned the expression of prototypical FOXO1 target genes in the 
expected manner, we failed to detect changes in components 
of the OGDH complex that would explain a reduction in enzy-
matic activity (Fig. 6a). Similar data were obtained at the protein 
level (Extended Data Fig. 8a). We therefore considered alterna-
tive mechanisms of regulation. Our initial metabolomics analysis 
showed that, besides 2HG, FOXO1 induces the accumulation of 
3-methyl-2-oxovalerate (KMV), 3-methyl-2-oxobutyrate (KIV) 
and 4-methyl-2-oxopentanoate (KIC), and other intermediates 
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Fig. 4 | OGDH inactivation induces S-2HG generation and limits endothelial proliferation. a, Metabolite levels of 2OG and succinyl-carnitine (a 
surrogate for succinyl-CoA) in HUVECs transduced with control (AdCtrl) or FOXO1A3-encoding (AdFOXO1A3) adenoviruses (n = 4 independent samples). 
b, Immunoblot analysis of OGDH protein abundance in control and OGDH-depleted HUVECs. Cells were generated by lentiviral transduction of 
FLAG-tagged Cas9 nuclease and control (gCtrl) or OGDH-targeting (gOGDH) gRNAs. c, OCRs in gCtrl- and gOGDH-transduced HUVECs under basal 
conditions and in response to FCCP (n = 8 independent samples). d, 2HG metabolite levels in gCtrl and gOGDH HUVECs measured by LC–MS (n = 7 
(gCtrl) and 8 (gOGDH) independent samples). e, Enantioselective LC–MS measurement of R- and S-2HG levels in gCtrl and gOGDH HUVECs (n = 7  
(gCtrl) and 8 (gOGDH) independent samples). f, Cell-proliferation curves comparing gCtrl and gOGDH HUVECs (n = 12 independent samples).  
g, EdU incorporation in control and OGDH-deficient HUVECs. The percentage of EdU-positive ECs is shown (n = 8 (gCtrl) and 12 (gOGDH) independent 
samples). h, EdU incorporation in control and cell-permeable 2OG-treated HUVECs. The percentage of EdU-positive ECs is shown (n = 5 independent 
samples). i, Immunoblot analysis of OGDH, SDHA and FH protein levels in control (gCtrl) and CRISPR–Cas9-engineered HUVECs (gOGDH, gSDHA or 
gFH). j, LC–MS measurement of 2HG enantiomers showing that OGDH-deficient HUVECs (gOGDH), but not SDHA- or FH-deficient cells, have increased 
S-2HG levels (n = 8, 7, 8 and 8 independent samples for gCtrl, gOGDH, gSDHA and gFH, respectively). k, EdU incorporation in gCtrl, gOGDH, gSDHA and 
gFH HUVECs. The percentage of EdU-positive ECs is shown (n = 5, 4, 4 and 4 independent samples for gCtrl, gOGDH, gSDHA and gFH, respectively). 
Western blot data in b and i are from the respective experiment, processed in parallel, and are representative of at least three independent experiments. 
For a, c, d–h, j and k, the data represent the mean ± s.e.m.; two-tailed unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS, not significant. 
The numerical data, unprocessed western blots and P values are provided as source data.
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are known inhibitors of OGDH34,38,44,45, which suggests that the 
FOXO1-induced increase in these branched chain α-keto acids 
(BCKAs) leads to inhibition of the OGDH complex. Consistent 
with this model, KMV reduced mitochondrial oxygen consump-
tion and OGDH activity, and led to a 9.7-fold increase in endo-
thelial S-2HG levels (Fig. 6e–h).
Genes involved in BCAA metabolism are direct FOXO1 tar-
get genes. We probed further to elucidate how FOXO1 regulates 
BCKA generation. Interrogation of the transcriptional signature 
of FOXO1A3-transduced HUVECs demonstrated that FOXO1 
induced several genes coding for enzymes of the BCAA catabolic 
pathway, including dihydrolipoamide branched chain transacyl-
ase E2 (DBT), branched chain keto acid dehydrogenase E1 subunit 
beta (BCKDHB), acyl-CoA dehydrogenase short/branched chain 
(ACADSB) and methylmalonyl-CoA mutase (MUT), among others 
(Fig. 7a,b and Extended Data Fig. 8b). Notably, DBT and BCKDHB 
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Fig. 5 | loss of endothelial OGDH restricts vascular growth. a,b, Control (Ogdhfl/fl, Ctrl) and endothelial-restricted Ogdh (Tie2-cre;Ogdhfl/fl, OGDHEC-KO) 
mutant yolk sacs (a) and embryos (b) at embryonic day 11. 5 (E11.5) showing reduced vascularization of the yolk sac and retarded development of the 
Ogdh knockout embryos. c, Confocal images of PECAM-stained (grey) P6 retinas isolated from control (Ogdhfl/fl) and inducible endothelial-specific Ogdh 
mutant mice (Cdh5-creERT2;Ogdhfl/fl; OgdhiEC-KO) following 4-OHT injection from P1 to P4. d, Immunofluorescence staining for ERG (cyan) and PECAM 
(red) in control and OgdhiEC-KO mice. e, Labelling of EdU (red), ERG (green) and PECAM (blue) of control and OgdhiEC-KO retinas at P6, revealing a decreased 
number of proliferating ECs (yellow) in OgdhiEC-KO mutants. f, Confocal images of cleaved caspase-3 (yellow), ICAM (cyan) and PECAM (red) labelling in 
retinas from control and OgdhiEC-KO mice. White arrowheads indicate apoptotic ECs. g, Quantification of retinal angiogenesis at P6 in control and OgdhiEC-KO 
mice (EC area: n = 10 (control) and 8 (OgdhiEC-KO) samples; number of ECs: n = 10 (control) and 9 (OgdhiEC-KO) samples; EC proliferation: n = 3 (control) 
and 5 (OgdhiEC-KO) samples). h, OGDH protein expression in ECs isolated from the lungs of Ogdhfl/fl mice followed by transduction with control (AdCtrl) 
or Cre-encoding (AdCre) adenoviruses. i, S-2HG metabolite levels in AdCtrl and AdCre-transduced lung ECs derived from Ogdhfl/fl mice (n = 3 (AdCtrl) 
and 5 (AdCre) independent samples). Western blot data in h are from the respective experiment, processed in parallel, and are representative of at least 
three independent experiments. For g and i, the data represent the mean ± s.e.m.; two-tailed unpaired t-test, **P < 0.01, ***P < 0.001, ****P < 0.0001. The 
numerical data, unprocessed western blots and P values are provided as source data.
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(BCKD) complex, which oxidizes KMV, KIC and KIV to 
branched-chain acyl-CoAs and constitutes the rate-limiting step in 
BCAA metabolism46. Moreover, expression of protein phosphatase, 
Mg2+/Mn2+-dependent 1K (PPM1K), a phosphatase that activates 
the BCKD complex46, was also increased by FOXO1, which suggests 
that FOXO1 coordinates the expression of genes involved in BCAA 
catabolism. Of note, FOXO1 regulates these genes independently of 
its repressive effects on MYC signalling4, since inactivation of MYC 
by CRISPR–Cas9 did not suppress the levels of these BCAA tran-
scripts (Extended Data Fig. 8c–e).
We therefore studied whether FOXO1 directly targets these 
genes, and conducted FOXO1 chromatin immunoprecipita-
tion with sequencing (ChIP-seq) in FOXO1A3-expressing ECs. 
We found that FOXO1 peaks were enriched for the high-affinity 
FOXO1-binding motif and were preferentially located at gene pro-





























































































































































































































































































































Fig. 6 | FOXO1 induces S-2HG generation by regulating BCAA catabolism. a, Expression of canonical FOXO1 targets and OGDH complex subunits in 
HUVECs transduced with a control-encoding (AdCtrl) and FOXO1A3-encoding (AdFOXO1A3) adenovirus. Cells were collected 24 h after transduction 
and analysed by RNA-seq (n = 3 independent samples). b, Volcano plot showing increased levels of BCAA catabolites in FOXO1A3-expressing HUVECs 
(n = 4 independent experiments). c, KMV metabolite levels in HUVECs transduced with a doxycycline-inducible control-encoding (iLentiCtrl) or 
FOXO1A3-encoding lentivirus (iLentiFOXO1A3) (n = 6 (iLentiCtrl) and 10 (iLentiFOXO1A3) independent samples). d, Changes in BCAA metabolites in AdCtrl 
versus AdFOXO1A3 expressing HUVECs. Data represent the fold-change relative to control (n = 4 independent samples). e, OGDH activity assay in control 
(PBS, Ctrl) or KMV-treated HUVECs (n = 3 independent experiments). f, Decreased basal and maximal (FCCP) OCRs in HUVECs treated with KMV for 
48 h compared to control (n = 5 (control) or 8 (KMV) independent samples). g, 2HG metabolite levels in control and KMV-treated HUVECs measured by 
LC–MS (n = 9 independent samples). h, 2HG chiral derivatization and enantioselective MS measurement of R- and S-2HG levels in control or KMV-treated 
HUVECs (n = 9 independent samples). For a–h, the data represent the mean ± s.e.m.; two-tailed unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. The numerical data and P values are provided as source data.
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9a,b). FOXO1 ChIP-seq identified bona fide FOXO1 targets, includ-
ing several of the differentially regulated BCAA genes (DBT, DLD, 
PPM1K, MUT and OXCT1) (Fig. 7c,d, Extended Data Fig. 9c–f and 
Supplementary Table 3). These FOXO1-bound genes were also in 
an active state, as indicated by the acetylation of H3K27 and the 
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Fig. 7 | The FOXO1-regulated BCAA catabolite KMV limits endothelial proliferation. a, Heatmap of genes involved in BCAA metabolism that are induced 
in FOXO1A3-expressing (AdFOXO1A3) HUVECs compared to control (AdCtrl). Transcript levels were assessed at 16, 24 and 32 h post-transduction and 
analysed by RNA-seq. Genes with a fold-change ≥2 and a P value of <0.05 are shown (n = 3 independent samples). b, RT–qPCR analysis validating 
the increased expression of BCAA metabolism genes in AdFOXO1A3-transduced HUVECs. Values are normalized to β-actin levels and represented as 
fold-change relative to control (n = 3 independent samples). c,d, FOXO1, H3K27ac and H3K4me3 ChIP-seq signals at the genomic loci of the DBT (c) 
and MUT (d) gene. FOXO consensus motifs bound by FOXO1 are indicated in orange. Unbound FOXO motifs are shown in grey. ChIP-seq signals are 
represented as reads per kilobase million. e, Cell-proliferation curves of HUVECs treated with vehicle (PBS, Ctrl) or KMV for the indicated times (n = 12 
independent samples). f, EdU incorporation is reduced in HUVECs treated with KMV for 48 h (n = 6 independent samples). g, Confocal images for PECAM 
(grey) labelling in P7 mouse retinas showing decreased vascular density after a single intraocular injection of KMV at P5. Mice injected with PBS were 
used as a control. h, Quantifications of vascular parameters in the retina of control and KMV-injected mice, as indicated (EC area: n = 20 (control) and 24 
(KMV) samples; EC branch points: n = 21 (control) and 24 (KMV) samples; EC proliferation: n = 21 (control) and 23 (KMV) samples). i, EdU (red), ERG 
(green) and PECAM (blue) labelling of control and KMV-injected retinas at P7, revealing decreased endothelial proliferation following KMV treatment. For 
b, e, f and h, the data represent the mean ± s.e.m.; two-tailed unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The numerical data and  
P values are provided as source data.
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These results demonstrate that FOXO1 drives a transcriptional pro-
gramme involved in BCAA catabolism and suggest a mechanism 
for the generation of BCKAs such as KMV.
BCAA metabolites restrict endothelial proliferation and vascu-
lar growth. Finally, we assessed the impact of BCKAs on ECs by 
treating HUVECs with KMV. Similar to S-2HG, KMV suppressed 
the proliferative activity of ECs without affecting their viability 
(Fig. 7e,f). Intraocular injection of KMV in neonatal pups (at P5) 
also reduced endothelial proliferation, giving rise to a sparse vascu-
lar network that resembled the vasculature in S-2HG-treated mice 
(Fig. 7g–i). Although we cannot exclude that KMV might also signal 
via alternative pathways, these data strongly suggest a pivotal role for 
KMV (and other BCKAs) in FOXO1-induced quiescence signalling.
Discussion
In summary, we identified a network of FOXO1-regulated metabo-
lites that promote the acquisition of a quiescent endothelial state, 
and in which the metabolic signalling molecule S-2HG plays a 
critical role. We propose that endothelial S-2HG levels increase 
in response to FOXO1 activation to induce a potent but reversible 
cell cycle arrest. Our data suggest that FOXO1 stimulates S-2HG 
generation by increasing BCKAs such as KMV, which inhibit the 
activity of the mitochondrial OGDH complex. Inhibition of this 
TCA cycle enzyme results in the accumulation of its substrate 2OG, 
which is subsequently reduced to S-2HG via promiscuous substrate 
usage34,35,37,38. Changes in endothelial FOXO1 activity therefore 
determine whether 2OG is used in the TCA cycle to support EC 
proliferation or is converted to S-2HG to signal quiescence. Our 
data are consistent with studies of several cancer cell lines showing 
that OGDH activity is necessary for cell proliferation47 and that S-
2HG can mount antiproliferative responses48,49.
The precise mechanisms by which S-2HG limits endothelial 
cell-cycle progression remain to be addressed. We found that S-2HG 
leads to increased HIF abundance and a robust HIF transcriptional 
response, which is in accordance with the inhibitory function of S-
2HG on PHD enzymes30,31,34,35 and the cell-cycle-arresting activity of 
HIFs50,51. Importantly, partial inactivation of PHD2 in ECs has also 
been shown to cause a resting (phalanx) phenotype via stabilization 
of HIF proteins52, which suggests that PHDs are quantitatively sen-
sitive targets of S-2HG that may contribute to its endothelial effects. 
In line with these reports, we found that genetic PHD inactivation 
lowers the proliferative capacity of ECs (Extended Data Fig. 10).
Yet, S-2HG inhibits a variety of other 2OG-dependent dioxygen-
ases, including JmjC histone lysine demethylases, ten-eleven trans-
location (TET) DNA hydroxylases and members of the AlkB family 
of proteins, which control histone, DNA and RNA methylation, 
respectively33,37–39,48,53. Although the vascular functions of these epi-
genetic regulators are largely unknown, it seems probable that they 
contribute to the effects of S-2HG in ECs. Future studies should aim 
to elucidate the role of these enzymes in the endothelium and assess 
their regulation by S-2HG and other small-molecule metabolites. 
Understanding such metabolic signalling mechanisms will provide 
insight into how blood vessels develop and are maintained, and how 
their functions become abnormal in disease states.
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Methods
Cells and cell culture. Pooled HUVECs were purchased from Lonza (CC-
2519) and cultured in endothelial basal medium (EBM; Lonza) supplemented 
with hydrocortisone (1 µg ml−1), bovine brain extract (12 µg ml−1), gentamicin 
(50 µg ml−1), amphotericin B (50 ng ml−1), human recombinant epidermal growth 
factor (10 ng ml−1) and 10% fetal bovine serum (FBS; Life Technologies). Human 
embryonic kidney cells (HEK293FT) were purchased from Life Technologies 
(R70007) and cultured in DMEM supplemented with 10% FBS (Life Technologies) 
and geneticin (500 µg ml−1; Invitrogen). Cells were tested negative for mycoplasma 
and maintained at 37 °C in a humidified atmosphere with 5% CO2.
The isolation of mouse lung ECs was performed as previously described4,54. 
In brief, lungs from adult Ogdhfl/fl mice were washed with ice-cold Hanks buffer 
(Gibco, 14175-053), dissociated into smaller fragments and incubated with 
dispase II (Gibco, 17105-041). The homogenate was filtered through a cell 
strainer, collected by centrifugation and washed with PBS (Gibco, 14190-094) 
containing 0.1% BSA (PBSB). The resulting cell suspension was incubated with 
rat anti-mouse VE-cadherin antibody-coated (BD Pharmingen, 555289) magnetic 
beads (Dynabeads, Invitrogen, 11035). Beads were washed with PBSB and then 
resuspended in D-MEM/F12 (Invitrogen) supplemented with 20% fetal calf 
serum (FCS), endothelial growth factor (Promocell, c-30140), penicillin and 
streptomycin. The isolated cells were seeded on gelatin-coated culture dishes and 
repurified with the VE-cadherin antibody during the first three passages.
Cell treatments. Cell-permeable (2R)-octyl-α-hydroxyglutarate (R-2HG; 16366) 
and (2S)-octyl-α-hydroxyglutarate (S-2HG; 16367) from Cayman Biochemical 
were reconstituted in dimethylsulfoxide (DMSO; Sigma, D4540). Cell-permeable 
2OG was obtained from Sigma (349631). For most studies, HUVECs were 
treated with 800 µM of R-2HG, S-2HG or 2OG, and DMSO was used as a vehicle 
control35,37,39,48. (±)-3-Methyl-2-oxovaleric acid sodium salt (KMV; Sigma, K7125) 
was reconstituted in PBS and used at 10 mM at the indicated time points. To block 
the PHD-dependent degradation of HIFs, cells were treated with 1 mM DMOG 
(Sigma, D3695) for 6 h. To inhibit autophagy, HUVECs were treated overnight 
with 50 µM chloroquine (Sigma, C6628). Endothelial apoptosis was induced by 
treating HUVECs with 10 µg ml−1 cycloheximide (Merck-Millipore, 239765) and 
10 ng ml−1 TNFα (TNF; Invitrogen, PHC3015) for 6 h. For cellular senescence 
studies, HUVECs were exposed to 100 µM hydrogen peroxide (H2O2) for 1 h. To 
measure changes in protein synthesis by surface sensing of translation (SUnSET)55, 
HUVECs were pulsed with 1 µg ml−1 puromycin (InvivoGen, ant-pr-1) for 15 min. 
Protein synthesis was blocked by pretreatment with 100 µM cycloheximide 
(Merck-Millipore, 239765) for 1 h before the puromycin pulse was applied.
Adenoviral transductions. Subconfluent HUVECs were transduced with 
custom-made adenoviruses (Vector Biolabs) to overexpress the FLAG-tagged 
human FOXO1A3 (AdFOXO1A3) that is constitutively nuclear4. Adenoviruses 
that contained an empty CMV promoter (AdCtrl; 1300, Vector Biolabs) were 
used as a control. For transductions, HUVECs were incubated in EBM (Lonza) 
containing 0.1% (v/v) BSA (Sigma, 1595) for 4 h and transduced with AdCtrl or 
AdFOXO1A3 for an additional 4 h in the presence of 8 µg ml−1 polybrene (Santa 
Cruz). Afterwards, HUVECs were washed five times with Hank’s balanced salt 
solution (Life Technologies) and cultured in EBM with 10% FBS and supplements. 
Adenoviral transductions of mouse lung ECs isolated from Ogdhfl/fl mice were 
performed with Cre-encoding adenovirus (AdCre, 1045, Vector Biolabs) or the 
respective control (AdCtrl).
Lentiviruses and lentiviral transductions. For doxycycline-inducible lentiviral 
expression of a constitutively nuclear human FOXO1 (FOXO1A3), FLAG-tagged 
FOXO1A3 was cloned into pLVX-TetOne-Puro (Clontech). For CRISPR–Cas9 
genome editing, gene-specific gRNA sequences (Supplementary Table 4) were 
cloned into a plentiCRISPRv2 plasmid co-expressing FLAG-tagged Cas9 nuclease 
and a puromycin-selection marker (Addgene, 52961). The FUCCI lentiviral 
reporters mCherry-hCdt1(30/120)-pCSII-EF and mVenus-hGeminin(1/11
0)-pCSII-EF56 were obtained from the Laboratory for Cell Function Dynamics, 
CBS, RIKEN, Japan.
Lentivirus production was performed by co-transfection of HEK293FT cells 
with pMD2.G (Addgene, 12259), psPAX2 (Addgene, 12260) and transfer plasmids, 
accordingly. Transfections were carried out using Lipofectamine 2000 transfection 
reagent (Life Technologies) as previously described57. Viruses were collected 48 
and 72 h after transfection, filtered through a 0.45-μm filter and incubated with 
HUVECs for 16 h in the presence of 8 µg ml−1 polybrene (Santa Cruz). After 
transduction, cells were expanded for 48 h and selected with EBM containing 
1 µg ml−1 puromycin (InvivoGen, ant-pr-1).
CRISPR–Cas9 genome editing of HUVECs. Gene-specific gRNA sequences were 
designed using the Genetic Perturbation Platform from the Broad Institute (https://
portals.broadinstitute.org/gpp/public/). For each target gene, three independent 
gRNAs were used and co-transfected with the packaging vectors for lentivirus 
production. After transduction, puromycin was used to select a pool of CRISPR–
Cas9-mediated mutant HUVECs. Knockout efficiency was confirmed by western 
blot analysis. Single gRNA sequences are provided in Supplementary Table 4.
Proliferation assays. HUVECs were seeded onto 6-well plates at a density of 
25,000 cells per well and left to attach overnight. Next day (0 h), the indicated 
treatments were added to the culture medium and total cell numbers were counted 
every 24 h. Cell culture medium was replaced every 48 h. For 3H-thymidine 
incorporation into DNA, HUVECs treated for 48 h with S-2HG or vehicle were 
pulsed with 1 μCi μl−1 3H-thymidine (Perkin Elmer) for 6 h before collection. 
Samples were processed as previously described18, and scintillation was measured 
with a liquid scintillation analyser (Tri-Carb 2810R, Perkin Elmer). Data were 
normalized to the total protein concentration per sample.
RNA and protein synthesis assays. RNA synthesis was measured by 14C-glucose 
incorporation into RNA. HUVECs were pulsed with 0.22 μCi μl−1 d-(6-14C)-glucose 
(Perkin Elmer) for 48 h before collection. Samples were processed and analysed 
as previously described58. Data were normalized to the total RNA concentration 
per sample. To measure protein synthesis by 3H-tyrosine incorporation into newly 
synthesized protein, HUVECs were pulsed with 1 μCi μl−1 3H-tyrosine (Perkin 
Elmer) for 6 h before collection. Samples were processed and analysed as previously 
described12. Data were normalized to the total protein concentration per sample.
Cell cycle analysis by flow cytometry and live-cell imaging. Cell cycle analysis 
of HUVECs was performed using a BrdU Flow kit (BD Pharmingen BrdU-APC 
Flow kit, 557892). HUVECs were pulsed with 10 µM BrdU in culture medium 
for 45 min before cell collection. Samples were further processed according to 
the manufacturer’s protocol and analysed by flow cytometry on a LSR Fortessa 
instrument (BD Biosciences). Analysis of endothelial cell-cycle dynamics was 
performed in HUVECs expressing the FUCCI reporter56 using an IncuCyte 
Live-Cell imaging system (Essen BioScience).
Western blotting. Cell lysates, subcellular fractionations and western blot analyses 
were performed as previously described59. The antibodies and amounts used are 
listed in Supplementary Table 5.
Spheroid assay. HUVECs resuspended in 80% EBM and 20% Methocel (v/v) 
were seeded onto a 96-well U-bottomed suspension cell culture plate for 24 h. 
Spheroids were collected, centrifuged at 200 × g for 5 min and resuspended in 80% 
(v/v) Methocel with 20% (v/v) FBS (Life Technologies). The spheroid–Methocel 
solution was mixed with equal volumes of collagen matrix and seeded onto a 
24-well plate. The plate was incubated for 30 min to allow polymerization and then 
supplemented with 100 µl of EBM with control vehicle (DMSO), 2OG or S-2HG. 
Endothelial sprouting was allowed for 24 h, after which the spheroid-containing 
gels were washed with PBS and fixed for 30 min at room temperature in 10% 
formaldehyde. Bright-field images were acquired, and angiogenic parameters 
assessed from at least five spheroids per condition. Spheroids were further labelled 
with Phalloidin-iFluor 488 (Abcam, 176753) overnight at 4 °C, and representative 
z-stack images were acquired by confocal microscopy.
Scratch-wound assay. Scratch-wound assays were performed using an IncuCyte 
Cell Migration kit (Essen BioScience, 4493). HUVECs (10,000 per well) were 
plated onto 96-well ImageLock microplates (Essen BioScience, 4379) and cultured 
overnight in EBM with 10% FBS and supplements. A uniform scratch-wound was 
generated using an IncuCyte 96-well WoundMaker (Essen BioScience) following 
the manufacturer’s instructions. Cells were washed three times with culture 
medium and cultured with EBM with 10% FBS, supplements and treatments. 
Images were taken every hour until wound closure. The wound area at 0 and 12 h 
was measured and the results are expressed as percentage of scratch closure.
Senescence-associated β-galactosidase staining. Senescence-associated 
β-galactosidase staining was performed using a kit from Cell Signaling Technology 
(9860S). For each sample, five representative images were used to quantify the 
number of cells positive for senescence-associated β-galactosidase. H2O2-treated 
HUVECs were used as a positive control. Images were acquired using a LSM800 
microscope (Zeiss) with a ×20 objective. Volocity (Perkin Elmer), Fiji/ImageJ, 
Photoshop (Adobe) and Illustrator (Adobe) software were used for image 
quantification and processing.
Immunohistochemistry of cell cultures. HUVECs were seeded on glass-bottom 
culture dishes (Mattek) coated with fibronectin (50 μg ml−1) and cultured at 37 °C 
and 5% CO2. To detect FOXO1 subcellular localization, sparse and dense HUVEC 
cultures were washed and fixed with 4% paraformaldehyde (PFA) for 20 min 
at room temperature. Permeabilization was performed in 1% (w/v) BSA, 10% 
(v/v) donkey serum and 0.5% (v/v) Tween-20 in PBS. Cells were labelled with 
anti-FOXO1 (Cell Signaling Technology, 2880; 1:100), anti-PECAM-1/CD31 (R&D 
Biosystems, AF3628; 1:200) and 4,6-diamidino-2-phenylindole (DAPI; 1 µg ml−1) 
diluted in incubation buffer (0.5% BSA, 5% donkey serum and 0.25% Tween-20 in 
PBS). Following washes in PBS with 0.1% (v/v) Tween-20 (PBST), HUVECs were 
incubated with Alexa-Fluor-conjugated secondary antibodies (Invitrogen; 1:1,000) 
diluted in incubation buffer for 2 h at room temperature. Cells were washed in 
PBST, mounted in VectaShield (Vector Laboratories, H-1000) and confocal images 
acquired using a SP8 confocal microscope (Leica). Labelling of proliferating cells 
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with EdU was performed using a Click-iT EdU imaging kit (Invitrogen). HUVECs 
were pulsed with 10 µM EdU in culture medium for 3 h before collection and 
further processed according to the manufacturer’s instructions.
Metabolomics analyses. Untargeted biochemical profiling of intracellular 
metabolites was measured using gas chromatography (GC)–MS and LC–MS/
MS platforms from Metabolon. Samples were normalized using the cell number 
and rescaled to set the median to 1. Missing values were imputed with the 
minimum value, and analyses performed with hierarchical clustering and PCA. 
For the analysis of 2HG in HUVECs transduced with the doxycycline-inducible 
lentiviruses, cells were seeded onto 60-mm dishes and treated with 100 ng ml−1 
doxycycline (Sigma) for 48 h before collection. For studies using sparse and dense 
cultures, HUVECs were seeded onto 60-mm dishes and cultured in EBM for 10 
days (dense cultures). Culture medium was regularly replaced every 2 days. To 
generate sparse cultures, dense cultures at day 8 were trypsinized and re-seeded 
to reinitiate proliferation 36 h before metabolite extraction. After the indicated 
experimental treatments, HUVECs were washed three times with ice-cold PBS 
(Life Technologies), and metabolites were collected with extraction buffer (50% 
(v/v) methanol, 30% (v/v) acetonitrile, 20% (v/v) ultrapure water and 100 ng ml−1 
HEPES). Thereafter, plates were incubated for 15 min over dry ice and methanol, 
samples collected by scraping onto Eppendorf tubes and incubated on dry ice for 
an additional 15 min. Tubes were incubated at 4 °C and shaken at 1,400 r.p.m. for 
15 min, and metabolite extracts were cleared by centrifugation at 14,000 r.p.m., 4 °C 
for 10 min. Finally, the supernatants were transferred into autosampler vials and 
stored at −80 °C before analysis. LC–MS analysis of sample extracts was performed 
on a QExactive Orbitrap mass spectrometer coupled to a Dionex UltiMate 3000 
Rapid Separation LC system (Thermo). The LC system was fitted with a SeQuant 
Zic-pHILIC (150 × 2.1 mm, 5 μm) with a guard column (20 × 2.1 mm, 5 μm) from 
Merck. The flow rate was set at 200 µL min−1 with the following gradient: 0 min 
80% B, 2 min 80% B, 17 min 20% B, 17.1 min 80% B, and a hold at 80% B for 5 min. 
The mass spectrometer was operated in full MS and polarity-switching mode. Five 
independent cell cultures were measured for each condition, and samples were 
randomized to avoid bias in sample analyses due to machine drift. The acquired 
spectra were analysed using XCalibur Qual Browser and XCalibur Quan Browser 
software (Thermo Scientific) by referencing to an internal library of compounds. 
The R packages muma and gplots were used for data visualization. Quantification 
of 2HG was performed via interpolation of the corresponding standard curve 
obtained from serial dilutions of dl-α-hydroxyglutaric acid disodium salt (Sigma, 
94577) running with the same batch of samples. Chiral derivatization of 2HG 
metabolite extracts with (+)-O,O′-diacetyl-l-tartaric anhydride (DATAN; Sigma, 
358924) was performed as previously described38,60, with some modifications. 
Briefly, for each sample, 300 μl of metabolite extract was evaporated to dryness 
at ambient temperature in a Savant SpeedVac concentrator (Thermo Scientific). 
The residue was resuspended in 75 μl of freshly prepared mixture of 80% 
acetonitrile/20% acetic acid (v/v) plus 50 mg ml−1 DATAN (Acros Organics) and 
incubated at 75 °C for 45 min. Samples were cooled to room temperature and 
centrifuged before the addition of 75 μl 80% acetonitrile/20% acetic acid. The 
derivatized sample (5 μl) was injected into a Acquity UHPLC HSS T3 column 
(100 × 2.1 mm, 1.8-μm particle size). A Dionex UltiMate 3000 Rapid Separation LC 
was coupled to a QExactive Orbitrap mass spectrometer, and a gradient elution of 
1.5 mM ammonium formate in water (mobile phase A, pH 3.6 adjusted with formic 
acid) and 0.1% formic acid in acetonitrile (mobile phase B) was used to separate 
the derivatized R- and S-2HG enantiomers. The target analytes were monitored 
by in parallel-reaction monitoring in negative electrospray ionization mode. The 
transition (precursor ion → product ion) of m/z 363 → 147 for derivatized R- and S-
2HG was monitored, and an accurate mass of 147.03 was extracted using XCalibur 
Qual Browser and XCalibur Quan Browser software (Thermo Scientific) and used 
for relative quantification. Experimental samples were randomized to avoid bias in 
sample analyses due to machine drift.
Metabolic assays. The OCR was measured using a Seahorse XFe96 analyser 
(Seahorse Bioscience). In brief, HUVECs (40,000 cells per well) were seeded onto 
fibronectin-coated XFe96 microplates. After 4 h, the medium was changed to a 
non-buffered assay medium and cells were maintained in a non-CO2 incubator 
for 1 h. Using a Mito Stress test kit (Seahorse Bioscience), the OCR was measured 
sequentially under basal conditions, after injection of oligomycin (3 µM), the 
mitochondrial uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenyl-hydrazone 
(FCCP; 1 µM) and after injection of a mix of the respiratory chain inhibitors 
antimycin A (1.5 µM) and rotenone (3 µM), as previously described4. OGDH 
activity and ATP levels were measured in HUVEC lysates (1 × 106 cells) using a 
OGDH activity assay kit (Sigma) and an ATP Bioluminescence Assay kit CLS II 
(Roche), respectively.
RNA-seq and GSEA. For RNA-seq, RNA was isolated from HUVECs using 
a miRNeasy micro kit (Qiagen) combined with on-column DNase digestion 
(DNase-Free DNase Set, Qiagen). RNA and library preparation integrity were 
verified using a LabChip Gx Touch 24 (Perkin Elmer). For input, 4 μg of total RNA 
was used for Truseq Stranded mRNA library preparation following the low-sample 
protocol (Illumina). Sequencing was performed on a NextSeq500 instrument 
(Illumina) using v2 chemistry, resulting in a minimum of 32 million reads per 
library with 1 × 75-bp single-end setup. Processing of raw reads was performed as 
previously described61. For GSEA62 and Gene Ontology terms analysis, gene set 
collections from the Molecular Signatures Database (MSigDB) 4.0 (http://www.
broadinstitute.org/gsea/msigdb/) were used. Heatmaps were generated using 
Morpheus (https://software.broadinstitute.org/morpheus/).
RT–qPCR. RNA isolation, complementary DNA synthesis and quantitative PCR 
with reverse transcription (RT–qPCR) were performed as previously described4. The 
human TaqMan Gene Expression assays used are listed in Supplementary Table 6.
ChIP assay. HUVECs were fixed with 1% formaldehyde for 15 min and quenched 
with 0.125 M glycine. Chromatin was isolated via the addition of lysis buffer, 
followed by disruption with a Dounce homogenizer. Lysates were sonicated, and 
the DNA sheared to an average length of 300–500 bp. Genomic DNA (input) was 
prepared by treating aliquots of chromatin with RNase, proteinase K and heat for 
reverse-crosslinking, followed by ethanol precipitation. Pellets were resuspended 
and the resulting DNA was quantified on a NanoDrop spectrophotometer. 
Extrapolation to the original chromatin volume allowed quantitation of the total 
chromatin yield. Sheared chromatin (30 μg) was precleared with protein A agarose 
beads (Invitrogen). Genomic DNA regions of interest were isolated using 4 μg 
of ChIP-grade antibodies against FOXO1 (Abcam, ab39670), H3K4me3 (Active 
Motif, 39159) and H3K27ac (Active Motif, 39133). Complexes were washed, 
eluted from the beads with SDS buffer and subjected to RNase and proteinase K 
treatment. Crosslinks were reversed by incubation overnight at 65 °C, and ChIP 
DNAs were purified by phenol–chloroform extraction and ethanol precipitation.
ChIP-seq. Illumina sequencing libraries were prepared from ChIP and input DNAs 
by the standard consecutive enzymatic steps of end-polishing, dA-addition and 
adaptor ligation. After a final PCR amplification step, the resulting DNA libraries 
were quantified and sequenced on Illumina’s NextSeq 500 (75-nt reads, single end). 
Reads were aligned to the human genome (hg38) using the Burrows–Wheeler 
algorithm63 (default settings). Duplicate reads were removed, and only uniquely 
mapped reads (mapping quality ≥ 25) were used for further analysis. Alignments 
were extended in silico at their 3′-ends to a length of 200 bp, which is the average 
genomic fragment length in the size-selected library, and assigned to 32-nt bins 
along the genome. The resulting histograms (genomic ‘signal maps’) were stored in 
bigWig files. Peak locations were determined using the MACS algorithm (v.2.1.0)64 
with a cut-off of P value of 1 × 10−7. Peaks that were on the ENCODE blacklist of 
known false ChIP-seq peaks were removed. Signal maps and peak locations were 
used as input data to Active Motifs proprietary analysis program, which creates 
tables containing detailed information on sample comparison, peak metrics, 
peak locations and gene annotations. Binding motifs were identified with the 
findMotifsGenome program of the HOMER package65 using default parameters 
and input sequences comprising ±100 bp from the centre of the top 1,000 peaks. 
Individual profiles were produced with a window of 5 bp. All profiles were plotted 
on a normalized reads-per-million basis. The processed data were plotted and 
visualized using software of the R project for statistical computing.
Animals, genetic experiments and intraocular injections. The conditional Ogdh 
knockout allele was generated by flanking exons 3 and 4 with loxP sites. Loss of 
exons 3 and 4 after Cre-mediated recombination results in a frameshift of the Ogdh 
gene. Mice were on a C57BL/6 genetic background and were generated by Cyagen 
Biosciences. For constitutive Cre-mediated recombination in ECs, Ogdhfl/fl mice 
(OgdhEC-KO) were bred with Tie2-cre transgenic mice66. To avoid recombination in 
the female germline, only Tie2-cre-positive male mice were used for intercrosses. 
Embryos were collected from cre-negative females at the indicated time points 
and genotyping performed from isolated embryos. For inducible Cre-mediated 
recombination in ECs, loxP-flanked Ogdh mice (Ogdhfl/fl) were bred with transgenic 
mice expressing the tamoxifen-inducible, Cdh5 promoter-driven creERT2 (ref. 67)  
(OgdhiEC-KO). For the analysis of angiogenesis in the postnatal mouse retina, 
Cre-mediated recombination was induced by intraperitoneal injections of 25 µl 
4-OHT (2 mg ml−1; Sigma) from P1 to P4. Eyes were collected at P6 for analysis. 
Control animals were littermate animals without Cre. Mice were genotyped by PCR 
performed on genomic DNA. Genomic DNA was extracted from tail biopsies using 
DirectPCR Lysis reagent (Peqlab). Intraocular administration of S-2HG (800 µM) 
and KMV (10 mM) into newborn mouse retinas was performed as previously 
described68. Briefly, a single dose of metabolites (0.25 µl) was injected into the 
vitreous cavity of P5 mice using a Nanoliter 2000 microinjector (World Precision 
Instruments). As controls, all pups were injected with S-2HG or KMV into the one 
eyeball and with the vehicle (DMSO or PBS, respectively) into the contralateral eye. 
Eyes were collected at P7 for further analysis by immunohistochemistry. Male and 
female mice (C57BL/6) were used for this experiment. All mice were maintained 
under specific pathogen-free conditions, and animal experiments were conducted 
in accordance with institutional guidelines and laws, following protocols approved 
by local animal ethics committees and authorities. The genetic experiments were 
approved by the Regierungspraesidium Darmstadt and the intraocular injections 
were performed under approval from the Institutional Animal Care and Use 
Committee of the Korea Advanced Institute of Science and Technology.
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Immunohistochemistry of murine retinal and yolk sac vasculature. To analyse 
blood vessel growth in the postnatal retina, whole mouse eyes were fixed in 4% 
(w/v) PFA on ice for 2.5 h. Eyes were washed in PBS and retinas were dissected 
and partially cut into four leaflets. After blocking and permeabilization in PBS 
containing 2% (v/v) FCS, 1% (w/v) BSA and 0.5% (v/v) Tween-20 for 1 h at room 
temperature, retinas were incubated overnight at 4 °C with the primary antibody 
diluted in PBS containing 1% (v/v) FCS, 0.5% (w/v) BSA, 0.25% (v/v) Tween-20 
and 0.25% (v/v) Triton X-100. Primary antibodies against the following proteins 
were used: collagen IV (Bio-Rad, 2150-1470; 1:400); cleaved (Asp175)-caspase3 
(Cell Signaling Technology, 9664; 1:100); ERG (Abcam, ab92513; 1:200); ICAM2 
(BD Biosciences, 553326; 1:200); and PECAM-1/CD31 (R&D Biosystems, AF3628; 
1:200). After four washes in PBST, retinas were incubated with Alexa-Fluor 488-, 
Alexa-Fluor 555-, Alexa-Fluor 594- or Alexa-Fluor 647-conjugated secondary 
antibodies (Life Technologies; 1:400) diluted in blocking buffer for 2 h at room 
temperature. After four washes in PBST, retinas were flat-mounted with ProLong 
Gold Antifade reagent (Life Technologies) and imaged by high-resolution 
confocal microscopy (Leica SP8). Labelling of proliferating cells with EdU was 
performed using a Click-iT EdU imaging kit (Invitrogen). Briefly, mouse pups 
were intraperitoneally injected with 25 µl of EdU (6 mg ml−1; Invitrogen) for 3 h 
before retinal collection, and EdU labelling was performed according to the 
manufacturer’s instructions.
For the analysis of the murine yolk sac vasculature, yolk sacs were flat-pinned 
on a silicon plate and fixed in 4% PFA on ice for 1 h followed by two washes in 
PBST. After blocking in 2% (v/v) donkey serum, 0.2% (w/v) BSA in PBST for 
2 h at room temperature, the yolk sacs were incubated overnight at 4 °C with the 
indicated primary antibody diluted in blocking buffer. After five washes in PBST, 
yolk sacs were incubated with Alexa-Fluor-conjugated secondary antibodies for 2 h 
at room temperature. Samples were washed four times with PBST, flat-mounted in 
ProLong Gold Antifade and imaged by confocal microscopy.
Immunostainings were carried out in tissues from littermates and processed 
under the same conditions. Volocity (Perkin Elmer), Fiji/ImageJ, Photoshop 
(Adobe) and Illustrator (Adobe) software were used for image acquisition and 
processing. For all of the images in which the levels of immunostaining were 
compared, settings for laser excitation and confocal scanner detection were kept 
constant between groups.
Quantitative analysis of the vasculature. All quantifications were done on 
high-resolution confocal images of thin z-sections of the sample using Volocity 
(Perkin Elmer) software. Endothelial coverage and the number of endothelial 
branch points were quantified behind the angiogenic front in a region between 
an artery and a vein. All parameters were quantified from a minimum of three 
vascularized fields per sample. Endothelial coverage was determined by assessing 
the ratio of the PECAM-positive area to the total area of the vascularized field 
(400 × 200 μm for murine retinas and 200 × 200 μm for yolk sac vasculature) 
and expressed as the percentage of the area covered by PECAM-positive ECs. 
The number of ECs (ERG-positive cells per field), the rate of proliferating ECs 
(EdU/ERG double-positive cells normalized to the number of ERG-positive 
cells) or vessel regression (number of ICAM2-negative, collagen-IV-positive 
basement membrane sleeves per 1,000-μm vessel segment) were also quantified 
in the same fields. The number of filopodial extensions was quantified at the 
angiogenic front as previously described69. All images shown are representative 
of the vascular phenotype observed in samples from at least three distinct litters 
per group.
Statistics and reproducibility. Statistical analysis was performed using unpaired, 
two-tailed Student’s t-test unless mentioned otherwise. For all bar graphs, data are 
represented as the mean ± s.e.m. P values of <0.05 were considered significant. All 
calculations were performed using Prism 8.0 (GraphPad Software).
No randomization or blinding was used for the analyses. Images are 
representative of at least three independent experiments in mice or cells of the 
same treatment group or genotype. Western blot data were from the respective 
experiment, processed in parallel and are representative of at least three 
independent experiments. Sample sizes were selected on the basis of published 
protocols69 and previous experiments.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Deep-sequencing (ChIP-seq and RNA–seq) data that support the findings of 
this study have been deposited in the Gene Expression Omnibus (GEO) under 
accession code GSE128636. All other data supporting the findings of this study are 
available from the corresponding author upon reasonable request. Source data are 
provided with this paper.
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Extended Data Fig. 1 | See next page for caption.
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Extended Data Fig. 1 | Foxo1 promotes a quiescent endothelial phenotype. a, Immunoblot analysis of quiescence-associated protein markers in HUVECs 
transduced with a FOXO1A3 (AdFOXO1A3) or control (AdCtrl) adenovirus. A FLAG antibody was used to validate the expression of the FLAG-tagged 
FOXO1A3 mutant. Tubulin served as loading control. b, Confocal images showing decreased EdU-incorporation in HUVECs transduced with AdFOXO1A3. 
The analysis was performed 24h after transduction. DAPI was used to identify endothelial nuclei. c, Quantification of EdU-incorporation in AdCtrl and 
FOXO1A3-expressing HUVECs. Values represent the percentage of EdU-labelled ECs, (n=6, 10 independent samples for AdCtrl and AdFOXO1A3). d, 2HG 
levels in AdCtrl- and AdFOXO1A3-transduced HUVECs measured by LC-MS, (n=4 independent samples). AU, arbitrary units. e, Immunoblot analysis 
of HUVECs transduced with a doxycycline-inducible control- (iLentiCtrl) or FOXO1A3-encoding lentivirus (iLentiFOXO1A3) showing expression of the 
FLAG-tagged FOXO1A3 mutant after doxycycline (Dox) treatment for 48h. The asterisk (*) denotes an unspecific protein detected by the FLAG antibody. 
f, Immunoblot analysis showing that the FOXO1-induced quiescence signature is reversible. HUVECs transduced with iLentiCtrl or iLentiFOXO1A3 were 
treated with Dox for 48h, after which Dox was removed from the culture media. HUVECs were then cultured for additional 48h. g, Quantitative RT-PCR 
(RT-qPCR) showing increased expression of canonical FOXO1 target genes in dense or sparse HUVEC cultures. Values are normalized to β-actin and 
represent fold-change regulation relative to control, (n=3 independent samples). Western blot data in a, e and f were from the respective experiment, 
processed in parallel, and are representative of at least three independent experiments. c, d and g, Data represent mean ± s.e.m.; a two-tailed unpaired 
t-test was used; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. The numerical data, unprocessed western blots and P values are provided as source data.
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Extended Data Fig. 2 | R- and S-2HG reduce the activity of 2-oxoglutarate-dependent dioxygenases in eCs. a, Immunoblot analysis of HIF1α and HIF2α 
protein abundance in HUVECs stimulated with cell-permeable R- or S-2HG for 24h. HUVECs treated with vehicle (DMSO) were used as a control (Ctrl). 
The PHD inhibitor DMOG, which stabilizes HIF protein levels, was used as a positive control. b, Heatmap of hypoxia associated genes that are differentially 
regulated in control (Ctrl) versus R-2HG or S-2HG-treated HUVECs. DMSO was used as a vehicle control. Cells were stimulated for 24h before total 
mRNA was collected for RNA-seq analysis, (n=3 independent samples). c, Gene set enrichment analysis (GSEA) showing a HIF gene expression signature 
in HUVECs treated with R- and S-2HG for 24h when compared to Ctrl. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate. 
d, Immunoblot analysis showing increased histone H3 lysine 27 tri-methylation (K27me3) levels in HUVECs treated with R-2HG or S-2HG when compared 
to Ctrl. Cells were analysed 24 or 48h after stimulation. Total levels of histone H3 are shown as protein loading control. Western blot data in a and d were 
from the respective experiment, processed in parallel, and are representative of at least three independent experiments. Unprocessed western blots are 
provided as source data.
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Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | S-2HG is a cell cycle-arresting metabolite. a, Proliferation curves comparing HUVECs treated with DMSO (Ctrl) or cell-permeable 
S-2HG, showing a dose-dependent reduction in S-2HG-stimulated HUVECs at the indicated concentrations and time points, (n=10 independent samples). 
b, Representative flow cytometry density plots showing the cell cycle phase distribution in HUVECs treated with vehicle (Ctrl) or S-2HG for 48 hours.  
c, Relative abundance of TCA cycle metabolites in Ctrl and S-2HG-treated HUVECs. LC-MS measurements were performed 48h after stimulation,  
(n=8 independent samples). d, Relative abundance of amino acids in Ctrl and S-2HG-treated HUVECs. LC-MS measurements were performed 48h after 
stimulation, (n=8 independent samples). e, Representative images and quantification of senescence-associated β-galactosidase (SA-β-Gal) staining 
showing that S-2HG does not induce cellular senescence. HUVECs were stimulated with DMSO (Ctrl) or S-2HG for 48h. Hydrogen peroxide (H2O2) 
stimulated cells were used as a positive control, (n=4 independent samples). f, LC3A/B immunoblot analysis showing that S-2HG treatment for 48h 
does not induce autophagy in ECs. Chloroquine (CQ) treated HUVECs were used as a positive control. g, Visualization of cell cycle progression using 
the dual fluorescence ubiquitination-based cell cycle indicator (FUCCI) reporter. Cells with red-labelled nuclei (expressing mCherry-hCdt1(30/120)) 
are in G0/G1 while cells with green labelled nuclei (expressing mVenus-hGeminin(1/110)) are in the S/G2/M cell cycle phase. Yellow nuclei indicate 
temporal co-expression of both reporters. h, Experimental timeline for the cell cycle analysis in HUVECs transduced with the FUCCI reporter. The ratio 
between green and red cells indicates the percentage of ECs in S/G2/M compared to G0/G1, respectively. Western blot data in f were from the respective 
experiment, processed in parallel, and are representative of at least three independent experiments. a and c-e, Data represent mean ± s.e.m.; a two-tailed 
unpaired t-test was used; *P<0.05; ** P<0.01; ***P<0.001; **** P<0.0001; NS, not significant. The numerical data, unprocessed western blots and P values 
are provided as source data.
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | S-2HG promotes a quiescent state in eCs. a, Gene ontology (GO) analysis showing top GO terms of genes that are downregulated 
in S-2HG-treated HUVECs as determined by RNA-seq analysis at 24h post treatment. DMSO-treated HUVECs were used as a control (Ctrl), (n=3 
independent samples). b, Heatmap showing the top down-regulated genes in the transcriptome of HUVECs treated with S-2HG for 24h. Transcripts 
highlighted in red are cell-cycle and proliferation related genes. c, GSEA plots of cell division and cell cycle phase transition gene sets in the transcriptomes 
of HUVECs treated with S-2HG or solvent (Ctrl) for 24h. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate. d, S-2HG 
decreases endothelial protein synthesis. Immunoblot analyses showing reduced incorporation of puromycin (PURO) into nascent polypeptide chains 
in whole-cell lysates of HUVECs treated with S-2HG or solvent (Ctrl) for 48h. Cycloheximide (CHX) stimulation was used as a positive control to block 
protein synthesis. Western blot data were from the respective experiment, processed in parallel, and are representative of at least three independent 
experiments. Unprocessed western blots are provided as source data.
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Extended Data Fig. 5 | S-2HG limits the angiogenic capacity of eCs. a, Quantifications of vascular parameters showing reduced endothelial sprouting 
capacity in S-2HG treated HUVEC spheroids, (n=5 independent samples). b, Experimental timeline for the retinal analysis after intraocular injection of 
a single dose of vehicle (DMSO, Ctrl) or S-2HG. The images of PECAM-labelled retinas on the right illustrate the extent of angiogenic growth between 
P5 and P7 in wild-type mice. c, Quantifications of vascular parameters in P7 Ctrl and S-2HG injected mouse retinas as indicated, (Number ECs: n=56, 51 
samples for Ctrl and S-2HG; Branching frequency: n=24, 25 samples for Ctrl and S-2HG; EC proliferation for Artery, Capillary and Vein: n=10, 10 samples 
for Ctrl and S-2HG). a and c, Data represent mean ± s.e.m.; a two-tailed unpaired t-test was used; *P<0.05; ** P<0.01; **** P<0.0001; NS, not significant. 
The numerical data and P values are provided as source data.
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | Changes in endothelial mitochondrial metabolism upon FOXO1A3 expression or OGDH depletion. a, Oxygen consumption rate 
(OCR) in control (iLentiCtrl) and FOXO1A3-transduced (iLentiFOXO1A3) HUVECs 48h after doxycycline induction. Oligo, oligomycin; FCCP, fluoro-carbonyl 
cyanide phenylhydrazone; AA / R, Antimycin A / Rotenone, (n=4 independent samples). b, Schematic representation showing the metabolic substrates 
and products catalysed by the TCA cycle enzymes OGDH, SDH and FH. c, Metabolite levels of 2-oxoglutarate (2OG) and succinate in control (gCtrl) and 
OGDH-depleted (gOGDH) HUVECs, (2OG: n=8, 8 independent samples for gCtrl and gOGDH; Succinate: n=5, 5 for gCtrl and gOGDH). AU, arbitrary units. 
d, Confocal images of phalloidin- (grey) labelled HUVEC spheroids showing that 2OG does not affect endothelial sprouting. Images were taken 24h after 
treatment. Quantifications are shown on the right, (n=3 independent samples). e, Scratch-wound assay quantification of vehicle (Ctrl) and 2OG-treated 
HUVECs, (n=5 independent samples). f-i, TCA cycle metabolite levels in control (gCtrl), SDHA- (gSDHA), OGDH- (gOGDH) and FH-depleted (gFH) 
HUVECs, (n=8 independent samples). AU, arbitrary units. j, EdU-incorporation in gCtrl, gSDHA, gOGDH and gFH transduced HUVECs. DAPI was used to 
identify endothelial nuclei. k, Oxygen consumption rate (OCR) in gCtrl, gOGDH, gSDHA and gFH depleted HUVECs. Measurements were performed under 
basal conditions and in response to FCCP stimulation, (n=6 independent samples). a, c-i and k, Data represent mean ± s.e.m.; a two-tailed unpaired t-test 
was used; ** P<0.01; ***P<0.001; **** P<0.0001; NS, not significant. The numerical data and P values are provided as source data.
NATuRe Cell BiOlOGY | www.nature.com/naturecellbiology
ArticlesNaTurE CEll BIOlOGy
Extended Data Fig. 7 | loss of endothelial Ogdh impairs vascular growth. a, Schematic illustration of the strategy to generate a conditional Ogdh knockout 
allele, in which exons 3 and 4 are flanked by loxP sites (red triangles). The Ogdh genomic locus, the targeting vector, the targeted allele and the SDA- and 
cre-recombined loci are shown. SDA-Neo-SDA, neomycin resistance cassette flanked by SDA sites. b, Immunofluorescence staining for ERG (cyan) and 
PECAM1 (PECAM, red) of control (Ctrl, Ogdhfl/fl) and endothelial-restricted Ogdh knockout (OgdhEC-KO, Tie2-cre;Ogdhfl/fl) yolk sacs at E11.5, showing reduced 
vascular density after Ogdh loss. c, Quantifications of vascular parameters in E11.5 Ctrl and OgdhEC-KO yolk sacs, as indicated, (EC area: n=7, 4 samples for 
Ctrl and OgdhEC-KO; Number of ECs: n=7, 4 samples for Ctrl and OgdhEC-KO). d, PCR analysis of genomic DNA from control (Ogdh+/+, lane 2; Ogdhfl/+,  
lane 3; Ogdhfl/fl, lane5) and conditional Ogdh mutant mice (Cdh5-creERT2; Ogdhfl/+, lane4; Cdh5-creERT2;Ogdhfl/fl, lane 6). Lane 1, DNA marker (M).  
e, Immunoblot analysis of OGDH protein levels in ECs isolated from the liver of 4-OHT-injected Ctrl (Ogdhfl/fl) and OgdhiEC-KO (Cdh5-creERT2;Ogdhfl/fl) mouse 
mutants. GAPDH served as loading control. f, Quantifications of vascular parameters in P6 Ctrl and OgdhiEC-KO mouse mutants, as indicated (Filopodia per 
vessel segment: n=10, 8 samples for Ctrl and OgdhiEC-KO; Branching frequency: n=10, 8 samples for Ctrl and OgdhiEC-KO; Regression index: n=5, 3 samples 
for Ctrl and OgdhiEC-KO). g, Immunostaining showing ICAM2- (ICAM, green), PECAM- (blue), and collagen IV- (COL, red) labelling of P6 retinas from 
4-OHT-injected Ctrl and OgdhiEC-KO mice. Western blot data in e were from the respective experiment, processed in parallel, and are representative of at 
least three independent experiments. c and f, Data represent mean ± s.e.m.; a two-tailed unpaired t-test was used; ** P< 0.01; ***P<0.001; ****P<0.0001; 
NS, not significant. The numerical data, unprocessed western blots and P values are provided as source data.
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Extended Data Fig. 8 | FOXO1 regulates genes involved in BCAA catabolism independent of its suppressive effect on MYC signalling. a, Immunoblot 
analysis in AdCtrl and AdFOXO1A3-transduced HUVECs showing the protein expression of the OGDH complex subunits. A FLAG antibody was used to 
validate the expression of the FLAG-tagged FOXO1A3 mutant. Tubulin served as loading control. b, Immunoblot analysis of the BCAA metabolism enzymes 
ACADSB, MUT and DBT in AdCtrl and AdFOXO1A3 transduced HUVECs. c, Immunoblot analysis of MYC protein levels in control and MYC-depleted 
HUVECs (gMYC). Cells were generated by lentiviral transduction with FLAG-tagged Cas9, control (gCtrl) or MYC (gMYC) targeting gRNAs. d, Gene set 
enrichment analysis (GSEA) showing a suppression of MYC-regulated genes in gMYC HUVECs when compared to controls (gCtrl). ES, enrichment score; 
NES, normalized enrichment score; FDR, false discovery rate. e, Expression of canonical MYC target genes and FOXO1-regulated BCAA genes in gCtrl 
and gMYC HUVECs. Analysis was performed by RNA-seq, (n=3 independent samples). Western blot data in a-c were from the respective experiment, 
processed in parallel, and are representative of at least three independent experiments. Data in e represent mean ± s.e.m.; a two-tailed unpaired t-test was 
used unless otherwise indicated; *P<0.05; **P< 0.01; ***P<0.001; ****P<0.0001; NS, not significant. The numerical data, unprocessed western blots and P 
values are provided as source data.
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Extended Data Fig. 9 | identification of FOXO1 target genes by ChiP-seq. a, Genome-wide analysis of FOXO1 binding peaks revealed the FOXO1 
high-affinity binding sequence as the most enriched motif in the immunoprecipitated chromatin of FOXO1A3-transduced HUVECs. b, Distribution of 
FOXO1 bindings peaks relative to the transcriptional start site (TSS), showing preferential binding of FOXO1 to genomic regions located at gene promoters 
near the TSS. c-f, ChIP-seq signals for FOXO1, H3K27Ac and H3K4me3 at the genomic loci of (c) OXCT1, (d) PDK1, (e) PDK4 and (f) MXI1. The FOXO 
consensus motifs that are bound by FOXO1 are highlighted in orange. ChIP-seq signals are represented as reads per kilobase million (RPKMs).
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Extended Data Fig. 10 | Genetic PHD inactivation lowers the proliferative activity of eCs. a, Immunoblot analysis of PHD1/2/3-depleted HUVECs 
showing regulation of HIF targets and proliferation-associated proteins. Cells were generated by lentiviral transduction with FLAG-tagged Cas9, control- 
(gCtrl) or PHD1/2/3-targeting gRNAs (gPHD1/2/3). b, EdU-incorporation in PHD1/2/3-depleted HUVECs. DAPI was used to identify ECs nuclei. 
c, Quantification of EdU-incorporation in gCtrl and gPHD1/2/3-transduced HUVECs. Values represent the percentage of EdU-labelled ECs, (n=20, 
24 independent samples for gCtrl and gPHD1/2/3). d, Reduced DNA synthesis in PHD1/2/3-depleted ECs, as assessed by analysing 3H-thymidine 
incorporation. Values are represented as fold-change relative to control, (n=6 independent samples). Western blot data in a were from the respective 
experiment, processed in parallel, and are representative of at least three independent experiments. c and d represent mean ± s.e.m.; a two-tailed unpaired 
t-test was used; **P< 0.01; ****P<0.0001. The numerical data, unprocessed western blots and P values are provided as source data.
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